Oncoinvent ASA Announces Positive Final 24-Month Follow-Up Results from Phase 1 Clinical Trial of Radspherin for Platinum-Sensitive Recurrent Ovarian Cancer

Strategic Insights -

Oncoinvent ASA, a clinical-stage radiopharmaceutical company, has announced positive final 24-month follow-up results from its Phase 1 clinical trial evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial aimed to eliminate post-surgery micro-metastases and prevent or delay peritoneal recurrence using direct intraperitoneal targeting with the alpha-emitter radium-224. The results showed that only 1 out of 10 patients who received the highest recommended dose of 7 MBq Radspherin had peritoneal recurrence after 24 months, with an overall recurrence rate of 30%. This is significantly lower than the expected recurrence rate of 55-60% in similar populations receiving standard care. The company plans to advance Radspherin as an innovative treatment for patients with peritoneal metastases as quickly as possible, citing the final results as "truly encouraging" and suggesting that Radspherin could help delay disease progression and offer patients hope for longer, healthier lives.

Key Takeaways:

  • The Phase 1 clinical trial evaluated Radspherin in 21 patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis.
  • The trial showed that 10 patients received the highest recommended dose of 7 MBq Radspherin, with only 1 patient experiencing peritoneal recurrence after 24 months.
  • The overall recurrence rate was 30%, which is significantly lower than the expected recurrence rate of 55-60% in similar populations receiving standard care.
  • The results suggest that Radspherin could help delay disease progression and offer patients hope for longer, healthier lives.
  • Dr. Luis Chiva, principal investigator, stated that the final results are "truly encouraging" and suggest that Radspherin could help delay disease progression.
  • Oncoinvent ASA plans to advance Radspherin as an innovative treatment for patients with peritoneal metastases as quickly as possible.

Statistics:

  • 21 patients received Radspherin in the Phase 1 clinical trial.
  • 10 patients received the highest recommended dose of 7 MBq Radspherin.
  • Only 1 patient experienced peritoneal recurrence after 24 months.
  • Overall recurrence rate was 30%.
  • 55-60% of patients in similar populations receiving standard care would expect disease recurrence at the 24-month time point.
  • Approximately 55-60% of patients in similar populations would expect disease recurrence at this time point.

Sources:

  • NewsRx LLC, "Oncoinvent ASA Announces Positive Final 24-Month Follow-Up Results from Phase 1 Clinical Trial of Radspherin for Platinum-Sensitive Recurrent Ovarian Cancer", 2025.